---
title: "FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) | GILD Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287393929.md"
description: "FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) | GILD Stock News"
datetime: "2026-05-22T10:00:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287393929.md)
  - [en](https://longbridge.com/en/news/287393929.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287393929.md)
---

# FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) | GILD Stock News

FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) | GILD Stock News

### Related Stocks

- [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)

## Related News & Research

- [<![CDATA[FDA Approves Hepcludex as First and Only Approved Treatment for Chronic Hepatitis Delta Virus]]>](https://longbridge.com/en/news/287656734.md)
- [ViiV Healthcare launches ‘PrEP Wisdom’ campaign](https://longbridge.com/en/news/288286441.md)
- [Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome](https://longbridge.com/en/news/288463750.md)
- [Biotech Stocks Facing FDA Decision In June 2026](https://longbridge.com/en/news/288591151.md)
- [Gilead Sciences Reports Positive Results From Phase 3 Study Of Livdelzi For Biliary Cholangitis](https://longbridge.com/en/news/288430891.md)